Hepatitis B reactivation after COVID-19: just a coincidence or a causal relationship?

Authors

DOI:

https://doi.org/10.59471/ijhsc2022119

Keywords:

Hepatitis B, Hepatitis B reactivation, COVID-19

Abstract

A 48 year-old man was evaluated because of a sudden raise in his liver function tests. He had a prior history of an acute hepatitis B infection, which spontaneously resolved in 2015 and a recent COVID-19 infection. As he only developed a mild disease, he did not receive steroids or convalescent plasma, or any other drugs. Seven weeks after having acquired the infection, he presented an acute hepatitis. Every known etiological factor was discarded. New serological status for hepatitis B was evaluated, and we discovered a sero-reversion. This situation could often be seen after immunosuppressive treatments, but our patient receive none of them. We started Entecavir and a rapid negativization of his viral load was observed as well as a normalization of his liver tests. If this reactivation was a consequence of COVID-19 or not is still not clear for us, but we believe that this case could raise awareness among physicians.

Downloads

Download data is not yet available.

References

Adhanom Ghebreyesus T. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

Xiaoqiang Chai, Longfei Hu, Yan Zhang. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection. bioRxiv 2020.02.03.931766. https://doi.org/10.1101/2020.02.03.931766

Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72(1):287-304. https://doi.org/10.1002/hep.31281.

Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology 2020;158:1518–1519. https://doi.org/10.1053/j.gastro.2020.02.054.

Aldhaleei WA, Alnuaimi A, Bhagavathula AS. COVID-19 Induced Hepatitis B Virus Reactivation: A Novel Case From the United Arab Emirates. Cureus. 2020;12(6):e8645. https://doi.org/10.7759/cureus.8645.

European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398. https://doi.org/10.1016/j.jhep.2017.03.021.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. http://doi.org/10.1002/hep.29800.

Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, Shen J, Zhu LR, Chen Y, Iacucci M, Ng SC, Ghosh S, Chen MH. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667-678. http://doi.org/10.1016/S2468-1253(20)30126-6.

Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, Poucke SV, Liu WY, Zheng MH. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol. 2020;8(1):18-24. http://doi.org/10.14218/JCTH.2020.00018.

Garrido I, Liberal R, Macedo G. Review article: COVID-19 and liver disease-what we know on 1st May 2020. Aliment Pharmacol Ther. 2020;52(2):267-275. https://doi.org/10.1111/apt.15813.

Downloads

Published

2022-12-02

How to Cite

1.
Gruz F, Rama P, Halac D. Hepatitis B reactivation after COVID-19: just a coincidence or a causal relationship?. Interamerican Journal of Health Sciences [Internet]. 2022 Dec. 2 [cited 2024 Jul. 21];(2):119. Available from: https://ijhsc.com/journal/article/view/119

Issue

Section

Clinical Cases and Case series

Categories